Cyclopharm Ltd
ASX:CYC
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.35
2.12
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CYC stock under the Base Case scenario is 2.01 AUD. Compared to the current market price of 1.38 AUD, Cyclopharm Ltd is Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cyclopharm Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CYC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cyclopharm Ltd
Balance Sheet Decomposition
Cyclopharm Ltd
Current Assets | 47.1m |
Cash & Short-Term Investments | 27.6m |
Receivables | 8.3m |
Other Current Assets | 11.2m |
Non-Current Assets | 17m |
PP&E | 10.4m |
Intangibles | 5.8m |
Other Non-Current Assets | 833.7k |
Current Liabilities | 10.7m |
Accounts Payable | 6.1m |
Other Current Liabilities | 4.7m |
Non-Current Liabilities | 5.8m |
Long-Term Debt | 4.7m |
Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
Cyclopharm Ltd
Revenue
|
29m
AUD
|
Cost of Revenue
|
-10.2m
AUD
|
Gross Profit
|
18.8m
AUD
|
Operating Expenses
|
-27.6m
AUD
|
Operating Income
|
-8.8m
AUD
|
Other Expenses
|
-541k
AUD
|
Net Income
|
-9.3m
AUD
|
Free Cash Flow Analysis
Cyclopharm Ltd
AUD | |
Free Cash Flow | AUD |
CYC Profitability Score
Profitability Due Diligence
Cyclopharm Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Cyclopharm Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CYC Solvency Score
Solvency Due Diligence
Cyclopharm Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Cyclopharm Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYC Price Targets Summary
Cyclopharm Ltd
According to Wall Street analysts, the average 1-year price target for CYC is 2.75 AUD with a low forecast of 2.73 AUD and a high forecast of 2.84 AUD.
Dividends
Current shareholder yield for CYC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CYC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
Contact
IPO
Employees
Officers
The intrinsic value of one CYC stock under the Base Case scenario is 2.01 AUD.
Compared to the current market price of 1.38 AUD, Cyclopharm Ltd is Undervalued by 31%.